Cholinesterases: Roles in the Brain During Health and Disease

Ballard, Clive G.; Greig, Nigel H.; Guillozet-Bongaarts, Angela L.; Enz, Albert; Darvesh, Sultan
July 2005
Current Alzheimer Research;Jul2005, Vol. 2 Issue 3, p307
Academic Journal
The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain, first emerged more than 20 years ago. The role for acetylcholinesterase (AChE) and its inhibition in this scheme has long been accepted, but findings from preclinical experiments and clinical trials have placed butyrylcholinesterase (BuChE) alongside AChE as an important contributor to the occurrence, symptoms, progression and responses to treatment in dementia. A number of new lines of evidence suggest that both cholinesterase inhibitors (ChEs) may have broader functions in the CNS than previously thought, which relate to both 'classical' esterase activities of the enzymes as well as non-classical actions unrelated to their enzymatic function. Data suggest involvement of the ChEs in modulating glial activation, cerebral blood flow, the amyloid cascade, and tau phosphorylation. It has therefore been speculated that some actions of the ChEs could affect the underlying disease processes in Alzheimer's disease (AD), and that pharmacological manipulation with ChE inhibitors may affect longterm disease progression. Focusing on new findings relating to BuChE, we review recent evidence that has extended knowledge into the roles of ChEs in health, disease and aging.


Related Articles

  • Rapid neurobehavioural analysis based on the effects of an acetylcholinesterase inhibitor from Tephrosia purpurea in Zebrafish. Kannan, Rajaretinam Rajesh; Prakash Vincent, Samuel Gnana // Annals of Neurosciences;Jan2012, Vol. 19 Issue 1, p8 

    Background: Zebrafish is an important model organism for human neurobehavioural studies and compound screening for neurodegenerative disorders like Alzheimer's disease and dementia. Purpose: We wanted to analyse the rapid neurobehavioural effects based on acetylcholinesterase inhibitors from...

  • An Active Approach. Bednar, Joseph // BusinessWest;10/13/2008, Vol. 25 Issue 11, p30 

    The article focuses on the specialized program for residents with memory diseases at the Ruth's House in East Longmeadow, Massachusetts. The program is called "Garden" and aims to help people with dementia or Alzheimer's disease cope up with their daily lives. The program which is a memory-care...

  • Blood Cells Cholinesterase Activity in Early Stage Alzheimer’s Disease and Vascular Dementia. Von Bernhardi, Rommy; Alarcón, Rodrigo; Mezzano, Diego; Fuentes, Patricio; Inestrosa, Nibaldo C. // Dementia & Geriatric Cognitive Disorders;2005, Vol. 19 Issue 4, p204 

    Blood acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities have been studied as markers for Alzheimer’s disease (AD), but their usefulness as a disease marker is controversial. To determine cholinesterase (ChE) activity during AD progression and whether ChE changes...

  • New Technology.  // Healthcare Purchasing News;Jul2007, Vol. 31 Issue 7, p58 

    The article presents an update on neurobehavioral disorders in the U.S. as of July 2007. A test was developed by researchers at San Francisco Veterans Administration Medical Center (SFVAMC) in California which predicts a patient's risk to dementia. The global prevalence of Alzheimer's disease is...

  • CHAPTER 44: ALZHEIMER'S DISEASE & DEMENTIA.  // Healthcare Business Market Research Handbook;2008, p176 

    Chapter 44 of "The 2008 Healthcare Business Market Research Handbook" is presented. It explores Alzheimer's disease which is said to be the most frequent cause of dementia and accounts for an estimate of 70% of all dementia cases in U.S. citizens age 71 and older. It also highlights the facts...

  • Spanish Version of the Bayer Activities of Daily Living Scale in Mild Cognitive Impairment and Mild Alzheimer Disease: Discriminant and Concurrent Validity. Sáchez-Benavides, G.; Manero, R. M.; Quiñones-Úda, S.; De Sola, S.; Quintana, M.; Peña-Casanova, J. // Dementia & Geriatric Cognitive Disorders;2009, Vol. 27 Issue 6, p572 

    Aims: To test the discriminant and concurrent validity of the Spanish version of the Bayer Activities of Daily Living scale (B-ADL) in mild cognitive impairment (MCI) and mild Alzheimer disease (AD). Methods: The B-ADL scale, the Blessed Dementia Rating Scale (BDRS), and the Interview for...

  • Cholinesterase inhibitors from botanicals. Ahmed, Faiyaz; Murad Ghalib, Raza; Sasikala, P.; Mueen Ahmed, K. K. // Pharmacognosy Reviews;Jul-Dec2013, Vol. 7 Issue 14, p121 

    Alzheimer's disease (AD) is a progressive neurodegenerative disease, wherein a progressive loss of cholinergic synapses occurs in hippocampus and neocortex. Decreased concentration of the neurotransmitter, acetylcholine (ACh), appears to be critical element in the development of dementia, and...

  • VASCULAR DEMENTIA: CHANGING CONCEPTS, CRITERIA, AND TREATMENT. Bowler, John V. // Current Medical Literature: Neurology;2005, Vol. 21 Issue 4, p69 

    The article discusses the concept of vascular dementia (VaD). There is an increased evidence for an important role for vascular disease in the context of other dementias. The fundamental flaws in the criteria for VaD are presented. The neuropsychological changes seen in VaD and Alzheimer's...

  • Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors. Hui Zhang; Kun Zou; Tesseur, Ina; Wyss-Coray, Tony // Current Alzheimer Research;Apr2005, Vol. 2 Issue 2, p183 

    Neurodegenerative and dementing illnesses are becoming an increasing social and economical burden as the number of older people continues to grow in industrialized countries. Current knowledge of the processes leading to these diseases is still limited, and very few effective treatments are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics